Current Neuropharmacology
Title: Preface
Volume: 1 Issue: 1
Author(s): Thomas E. Salt
Affiliation:
Export Options
About this article
Cite this article as:
E. Salt Thomas, Preface, Current Neuropharmacology 2003; 1 (1) . https://dx.doi.org/10.2174/1570159033360520
DOI https://dx.doi.org/10.2174/1570159033360520 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
11
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Current Topics in Medicinal Chemistry Aptamer-Targeted Oligonucleotide Theranostics: A Smarter Approach for Brain Delivery and the Treatment of Neurological Diseases
Current Topics in Medicinal Chemistry Being or Feeling the Right Weight: A Study of Their Interaction with Depression among Adolescents
Adolescent Psychiatry Drug Targets in Stress-Related Disorders
Current Medicinal Chemistry Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms
Current Pharmaceutical Design Inhibition of Neurogenesis by Zika Virus Infection
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 2
Current Rheumatology Reviews Surface Modified Self-Nanoemulsifying Formulations (SNEFs) For Oral Delivery of Gentamicin: In Vivo Toxicological and Pre- Clinical Chemistry Evaluations
Current Nanomedicine Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Current Genomics Drug release from ordered mesoporous silicas
Current Pharmaceutical Design Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Halogenated Derivatives of Aromatic Amino Acids Exhibit Balanced Antiglutamatergic Actions: Potential Applications for the Treatment of Neurological and Neuropsychiatric Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Novel Targets for Drugs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Sulfotransferase Inhibition: Potential Impact of Diet and Environmental Chemicals on Steroid Metabolism and Drug Detoxification
Current Drug Metabolism Inhibition of Opioid Receptor Mediated G-Protein Activity After Chronic Administration of Kynurenic Acid and its Derivative without Direct Binding to Opioid Receptors
CNS & Neurological Disorders - Drug Targets Schizophrenia and Liver Dysfunction Caused by Portacaval Shunting
Current Psychiatry Reviews The Role of NPY and Ghrelin in Anorexia Nervosa
Current Pharmaceutical Design Metabotropic Glutamate Receptors in the Trafficking of Ionotropic Glutamate and GABAA Receptors at Central Synapses
Current Neuropharmacology Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]
Current Pharmaceutical Design